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Background: Solifenacin succinate is a competitive muscarinic acetylcholine receptor antagonist used in the treatment
of overactive bladder with or without urge incontinence.
Methods: Liquid chromatography–tandem mass spectrometry method was used for quantification of Solifenacin
(SF) in rat plasma. Solifenacin-d5 (SFD5) used as an internal standard. Chromatographic separation was performed
Gemini-NX C18, 50 × 4.6 mm, 5 µm, 110 Å column. Mobile phase composed of 5 mM Ammonium formate, pH 3.0:
methanol (20:80 v/v), with 0.4 mL/min flow-rate. Drug and IS were extracted by Liquid- liquid extraction method. SF
and SFD5 were detected with proton adducts at m/z 363.2®193.2 and 368.2®198.2 in multiple reaction monitoring
(MRM) positive mode respectively. The method was validated with the correlation coefficients of (r2) ≥ 0.9975 over a
linear concentration range of 0.1-100.0 ng/mL.
Results: This method demonstrated intra and inter-day precision within 1.09 to 4.84 and 1.75 to 7.68 % and accuracy
within 101.21 to 106.67 and 97.94 to 104.79 % for SF.
Conclusions: This method is successfully applied in the Pharmacokinetic study of rat plasma.
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Solifenacin succinate is a competitive muscarinic acetyl-
choline receptor antagonist used in the treatment of
overactive bladder with or without urge incontinence.
Chemically, it is 1-azabicyclo[2.2.2]oct-8-yl(1S)-1-phenyl-
3,4-dihydro-1H-isoquinoline-2-carboxylate.
The molecular formula of Solifenacin succinate is
C23H26N2O2 with its molecular weight 362.46. Solifenacin
is extensively metabolized in the liver. One pharmacologic-
ally active metabolite (4R-hydroxy Solifenacin) occurs at
low concentrations and three pharmacologically inactive
metabolites (N-glucuronide and the N-oxide and 4R-
hydroxy-N-oxide of Solifenacin) in human plasma after oral
dosing. After oral administration of vesicare to healthy* Correspondence: rihanaparveen@gmail.com
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reproduction in any medium, provided the origvolunteers, peak plasma levels (Cmax) of Solifenacin reached
within 3 to 8 h after administration and at steady state
ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg
vesicare tablets, respectively. The terminal elimination half-
life of Solifenacin (SF) is approximately 45 to 68 h.
Solifenacin is approximately 98% (in vivo) bound to
human plasma proteins, principally to alpha1-acid glyco-
protein (Morales-Olivas and Estan 2010; Doroshyenko
and Fuhr 2009; Hoffstetter and Leong 2009; Kuipers et al.
2004; Leone Roberti Maggiore et al. 2012; Uchida et al.
2004; Yamada et al. 2012; Maruyama et al. 2008; Kuipers
et al. 2006; Callegari et al. 2011).
Literature survey reveals that quantification of Solifenacin
in human plasma (Macek et al. 2010; Mistri et al. 2008),
rat plasma (Yanagihara et al. 2007), pharmaceutical
compounds (Krishna et al. 2010; Desai et al. 2012; Rami
Reddy et al. 2013; Desai et al. 2011), and industrial waste
streams (Ann-Marie et al. 2011) were reported. Theses is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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electrospray ionization-tandem mass spectrometry (LC-MS/
MS) (Macek et al. 2010; Mistri et al. 2008; Ann-Marie et al.
2011), high-performance liquid chromatography (HPLC)
(Yanagihara et al. 2007; Krishna et al. 2010; Desai et al. 2012;
Rami Reddy et al. 2013), and HPTLC (Desai et al. 2011).
Among all, quantification of Solifenacin by LC-MS/MS in
biological matrices (Macek et al. 2010; Mistri et al. 2008;
Yanagihara et al. 2007) was proved best results.
Macek et al. 2010 reported with the linearity range of
0.47 to 42 ng/mL and used PPT method for extraction
of drug and internal standard (IS). They used 250 μL of
plasma sample for extraction procedure and obtained
good chromatography within 3 min run time. They used
Solifenacin d5 as an internal standard. Mistri et al.
(2008) reported with the linearity range of 0.6 to 60 ng/mL
and used liquid-liquid extraction (LLE) method for extrac-
tion of drug and IS. They used 500 μL of plasma sample
for extraction procedure and obtained good chromatog-
raphy with in 3 min run time. They used propranolol as
an internal standard. (Yanagihara et al. 2007) reported
with the linearity range of 2.0 to 2,000.00 ng/mL and used
LLE method for extraction of drug and IS. They used
1,000 μL of plasma sample for extraction procedure and
obtained good chromatography within 25 min run time.
They used ((−)-[(1R or 1S),3_R]-quinuclidin-3_-yl 1-benzyl-
1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydrochlo-
ride as an internal standard.
The reported methods have some drawbacks in terms
of large amount of plasma sample usage, lower sensitiv-
ity (Macek et al. 2010; Mistri et al. 2008; Yanagihara
et al. 2007), long run analysis time, and internal stand-
ard usage (Yanagihara et al. 2007). The main goal of
the present study is to develop and validate the novel
simple, higher sensitive, selective, rapid, rugged, and
reproducible bioanalytical method for quantitative
determination of SF in rat plasma by LC-MS/MS with
a small amount of sample volume. The developed
method would be applied in the pharmacokinetic study
of rat plasma.Figure 1 Chemical structures of Solifenacin (A) and Solifenacin d5 (B)Methods
Chemicals and reagents
Solifenacin succinate, Solifenacin d5 hydrochloride obtained
from Hetero Drugs, Hyderabad, India (Figure 1). HPLC
grade methanol was purchased from Jt. Baker Mallinckrodt
Baker, Inc., Phillipsburg, NJ, USA. Formic acid was pur-
chased from S.D. Fine Chemicals, Mumbai, India. Diethyl
ether was purchased from Merck Speciality Private Limited,
Worli, Mumbai, India. Ultrapure water from Milli-Q system
(Millipore, Bedford, MA, USA) was used through the study.
All other chemicals in this study were of analytical grade.
Rats were obtained from Bioneeds, Bangalore, Karnataka,
India.
Instrumentation
HPLC system (1200 Series Agilent Technologies,
Deutschland, Germany) connected with triple quadrupole
mass spectrometer instrument (API 4000, Toronto,
Canada). Data processing was performed with the Analyst
1.5.1 software package (SCIEX, Framingham, MA 01701,
USA). Ionization was performed by electrospray positive
mode with unit resolution.
Detection
Mass parameters were optimized to get the product ions of
m/z, 193.2 and m/z, 198.2 from its respective precursor
ions of SF [M+H]+ (m/z, 363.2) and SFD5 [M+H]+ (m/z,
368.2) with source temperature 500°C, ion spray voltage
5,500 V, heater gas, nebulizer gas 35 psi each, curtain gas
20 psi, CAD gas 5 psi (all gas channels with nitrogen),
source flow rate 400 μL/min without split, entrance poten-
tial 10 V, declustering potential 55 V for analyte and 65 V
for internal standard, collision energy 25 V for both analyte
and internal standard, and collision cell exit potential 13 V
for analyte and 12 V for internal standard.
Chromatographic conditions
Chromatography was performed using Gemini-NX C18,
50 × 4.6 mm, 5 μm, 110 Å analytical column at 30°C, with
5 mM ammonium formate, pH 3.0/methanol (20:80 v/v) as.
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as an internal standard in terms of chromatography and
extractability. The drug and internal standard was eluted at
1.2 ± 0.2 min with 2 min total run time.
Preparation of standards and quality control samples
Standard stock solutions of SF (50.0 μg/mL) and SFD5
(50.0 μg/mL) was prepared in methanol. The internal
standard spiking solution (50.0 ng/mL) was prepared in
water from SFD5 standard stock solution (50.0 μg/mL).
Standard stock solutions and internal standard spiking
solutions were stored in refrigerator conditions (2°C to 8°C)
until analysis. Standard stock solution of SF was added to
screened drug-free rat plasma to obtain concentration
levels of 0.1, 0.2, 1.0, 5.0, 10.0, 40.0, 60.0, 80.0, and
100.0 ng/mL for analytical standards and 0.1, 0.3, 50.0,
75.0 ng/mL for quality control (QC) standards and stored
in a −30°C freezer until analysis. Respective aqueous
standards were prepared in reconstitution solution (5 mM
ammonium formate pH 3.0/methanol (20:80) and stored
in refrigerator conditions 2°C to 8°C until analysis.Figure 2 Mass spectra of (A) Solifenacin parent ion and (B) SolifenaciSample preparation
Liquid-liquid extraction was used to isolate drug and IS
from rat plasma. For this purpose, 50 μL of IS (40.0 ng/mL)
and 100 μL of plasma sample (respective concentration)
was added into labeled polypropylene tubes and vortexed
briefly. Followed by 2.5 mL of extraction solvent (diethyl
ether) was added and vortexed for 10 min. Then, the
samples were centrifuged at 4,000 rpm for 10 min at 20°C
temperature. Subsequently, the supernatant from each
sample was transferred into respective polypropylene tubes.
After that, all the samples were kept for evaporation under
nitrogen at 40°C. The dried residue was reconstituted with
1,000 μL of reconstitution solution (5 mM ammonium
formate pH 3.0/methanol (20:80)) and vortexed briefly.
Finally, the extracted sample was transferred into auto
sampler vials and injected into LC-MS/MS.
Selectivity and specificity
The selectivity of the method was determined by six differ-
ent rat blank plasma samples, which were pretreated and
analyzed to test the potential interferences of endogenousn product ion.
Figure 3 Mass spectra of (A) Solifenacin d5 parent ion and (B) Solifenacin d5 product ion.
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graphic peaks of analyte and IS were identified based on
their retention times and multiple reaction monitoring
(MRM) responses. The peak area of SF at the respective re-
tention time in blank samples should not be more than
20% of the mean peak area of limit of quantification (LOQ)
of SF. Similarly, the peak area of SFD5 at the respective
retention time in blank samples should not be more than
5% of the mean peak area of LOQ of SFD5.
Recovery
The extraction recovery of SF and SFD5 from rat plasma
was determined by analyzing quality control samples. Re-
covery at three concentrations (1.5, 25.0, and 35.0 ng/mL)
was determined by comparing peak areas obtained from
the plasma sample and the standard solution spiked with
the blank plasma residue. A recovery of more than 85%
was considered adequate to obtain required recovery.Matrix factor ¼ Peak response ratio in presence of ex
Peak response ratio in aLimit of detection and limit of quantification
The limit of detection (LOD) is a parameter that provides
the lowest concentration in a sample that can be detected
from background noise but not quantitated. LOD was de-
termined using the signal-to-noise ratio (S/N) of 3:1 by
comparing test results from samples with known concen-
trations of analytes with blank samples.
The LOQ is defined as the lowest concentration of
analyte that can be determined with acceptable precision
and accuracy. The LOQ was found by analyzing a set
of mobile phase and plasma standards with a known
concentration of SF.
Matrix effect
To predict the variability of matrix effects in samples
from individual subjects, matrix effect was quantified by
determining the matrix factor, which was calculated as
follows:tracted matrix post extractedð Þ
queous standards
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each in triplicates and postspiked with the aqueous
standard at the low and high QC level and compared
with aqueous standards of same concentration. The
overall precision of the matrix factor is expressed as co-
efficient of variation (%CV) and %CV should be <15%.
Calibration curve, precision, and accuracy
The calibration curve was constructed using values ran-
ging from 0.1 to 100.0 ng/mL of SF in rat plasma. Cali-
bration curve was obtained by linear model with
weighted 1/x2 regression analysis. The ratio of SF/SFD5
peak area was plotted against the ratio of SF concentra-
tion in ng/mL. Calibration curve standard samples and
quality control samples were prepared in replicates (n =
6) for analysis. Precision and accuracy for the back-
calculated concentrations of the calibration points,
should be within ≤15 and ± 15% of their nominal values.
However, for LLOQ, the precision and accuracy should
be within ≤20 and ±20%.
Stability (freeze - thaw, auto sampler, bench top,
long-term) of SF in plasma
Low-quality control and high-quality control samples (n =
6) were retrieved from a deep freezer after three freeze-Figure 4 Chromatogram of Solifenacin and Solifenacin d5 in blank plthaw cycles according to the clinical protocol. Samples
were stored at −30°C in three cycles of 24, 36 and 48 h. In
addition, the long-term stability of SF in quality control
samples was also evaluated by analysis after 45 days of
storage at −30°C. Autosampler stability was studied fol-
lowing 61.5-h storage period in the autosampler tray with
control concentrations. Bench top stability was studied for
25-h period with control concentrations. Stability samples
were processed and extracted along with the freshly
spiked calibration curve standards. The precision and ac-
curacy for the stability samples must be ≤15 and ±15%, re-
spectively, of their nominal concentrations.
Application to pharmacokinetic study
The developed LC-MS/MS method was successfully ap-
plied to a pharmacokinetic study by administration of SF
to six male Sprague-Dawley rats by oral route using BD
syringe attached with oral gavage needle (size 18) at the
dose of 4 mg/200 g body weight. Required quantity of
test item (4 mg SF) was accurately weighed and trans-
ferred to a mortar and triturated with 2% (w/w) Tween
80 using a pestle to make a smooth paste. Then, 0.5%
(w/w) carboxymethyl cellulose (CMC) was gradually
added and suspended to make a required concentration
(1 mg/mL of SF). The final suspension was kept underasma (A), blank + IS (B), and LOQ (C).









0.10 0.11 0.01 6.46 110.40
0.20 0.19 0.01 4.78 95.40
1.00 0.97 0.01 1.33 97.10
5.00 5.12 0.16 3.17 102.32
10.00 10.10 0.09 0.94 101.00
40.00 39.68 0.39 0.98 99.19
60.00 59.89 0.63 1.05 99.82
80.00 80.74 0.68 0.84 100.92
100.00 99.55 0.35 0.35 99.55
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mately, 0.2 mL of blood samples from each anesthetized
(isoflurane) rat at pre-determined time intervals was col-
lected from the retro-orbital plexus using a capillary
tube into pre-labeled eppendorf tubes containing 10% of
K2EDTA anticoagulant (20 μL). The time intervals for
the sample collection were 0 (predose), 0.5, 1, 2, 3, 4, 5,
6, 8, 16, 24, 36, 48, and 72 h (postdose). The total blood
volume collected from each rat was approximately 1.9 to
2.2 mL which does not exceed the maximal recom-
mended blood volume of 20% (2.0 mL for a 200 g body
weight rat). Plasma was obtained by centrifuging blood
samples at 3,000 rpm for 10 min. The obtained plasma
samples were transferred into pre-labeled microcentri-
fuge tubes and stored at −30°C. All the samples were an-
alyzed by the developed method. Pharmacokinetic
parameters were calculated by non-compartmental ana-
lysis by using Win Nonlin® 5.1 software. Concentrations
obtained from the above bio-analytical method were
compiled (FDA 2002; FDA 2003).Results and discussion
Method development and method validation
LC-MS/MS has been used as one of the most powerful
analytical tools in clinical pharmacokinetics for its se-
lectivity, sensitivity, and reproducibility. The goal of this
work is to develop and validate a simple, sensitive, rapid,
rugged, and reproducible assay method for the quantita-




Concentration measured (n = 6)
(ng/mL) (mean ± S.D)
(CV %) Accura
0.10 0.11 ± 0.01 4.84 106
0.30 0.32 ± 0.01 2.58 105
50.00 50.61 ± 0.55 1.09 101
75.00 79.20 ± 1.18 1.49 105Chromatographic conditions, especially the composition
and nature of the mobile phase, usage of different col-
umns, and different extraction methods such as solid
phase, precipitation, and liquid-liquid extraction
methods were optimized through several trials to
achieve the best resolution and increase the signal of SF
and SFD5. The MS optimization was performed by dir-
ect infusion of solutions of both SF and SFD5into the
ESI source of the mass spectrometer. The critical param-
eters in the ESI source that include the needle (ESI) volt-
age, capillary voltage, source temperature, and other
parameters such as nebulizer gas, heater gas, and deso-
lvation gasses were optimized to obtain a better spray
shape, resulting in better ionization of the protonated
ionic SF and SFD5 molecules. Product ion spectrum for
SF and SFD5 yielded high-abundance fragment ions of
m/z 193.2 and m/z 198.2, respectively (Figures 2 and 3).
After mass spectrometer parameters optimized, chroma-
tographic conditions such as mobile phase optimization,
column optimization, and extraction method
optimization was performed to obtain a fast and select-
ive LC method.
A good separation and elution were achieved using
5 mM ammonium formate, pH 3.0/methanol (20:80 v/v)
as the mobile phase at a flow rate of 0.4 mL/min and in-
jection volume of 5 μL. Gemini-NX C18, 50 × 4.6 mm,
5 μm, 110 Å column, and liquid-liquid extraction method
was optimized for the best chromatography (Figure 4).
The developed method was validated over a linear con-
centration range 0.1 to 100.0 ng/ml. The validation pa-
rameters that include selectivity and specificity, LOD and
LOQ, matrix effect, precision and accuracy, recovery, sta-
bility (freeze - thaw, auto sampler, bench top, long-term)
were evaluated under validation section (FDA 2001).
Selectivity and specificity
The analysis of SF and SFD5 using MRM function was
highly selective with no interfering compounds. Chromato-
grams obtained from plasma spiked with SF (0.1 ng/mL)
and SFD5 (50.0 ng/mL) are shown in Figure 4.
Limit of detection and quantification
The limit of detection was used to determine the instru-
ment detection levels for SF even at low concentrations.Interday
cy (%) Concentration measured
(n = 30) (ng/mL) (mean ± S.D.)
(CV %) Accuracy (%)
.67 0.10 ± 0.01 7.68 98.53
.56 0.29 ± 0.04 3.60 97.94
.21 50.84 ± 0.75 1.48 101.67
.60 78.59 ± 1.38 1.75 104.79
Table 4 Mean pharmacokinetic parameters of Solifenacin
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and estimated LOD was 3.2 fg with S/N values ≥3 to 5.
The limit of quantification for this method was proven
as the lowest concentration of the calibration curve
which was proven as 0.1 ng/ml.AUC0−t (ng · h/mL) 1,029.81
Cmax (ng/mL) 17.98




AUC0−∞, area under the curve extrapolated to infinity; AUC0−t, area under the
curve up to the last sampling time; Cmax, the maximum plasma concentration;
Tmax, the time to reach peak concentration; Kel, the apparent elimination
rate constant.Matrix effect
Six lots of blank biological matrices were extracted each
in triplicates and postspiked with the aqueous standard
at the mid-QC level and compared with neat standards
of the same concentration in alternate injections. The
overall precision of the matrix factor is 3.45 for Solifena-
cin. There was no ion suppression and ion enhancement
effect observed due to IS and analyte at respective reten-
tion time.Precision and accuracy
Calibration curves were plotted as the peak area ratio
(SF/SFD5) versus (SF) concentration. Precision and ac-
curacy of calibration curve standards and quality control
standards are represented in Tables 1 and 2.Stability (freeze - thaw, auto sampler, bench top, long-term)
Quantification of the SF in plasma subjected to three
freeze-thaw cycles (−30°C to room temperature), auto-
sampler, room temperature (benchtop), and long-term
stability details was shown in Table 3.Recovery
The recovery following the sample preparation using
liquid-liquid extraction with diethyl ether was calculated
by comparing the peak area of SF in plasma samples
with the peak area of solvent samples and was estimated
at control levels of SF. The recovery of SF was deter-
mined at three different concentrations; 1.5, 25.0, and
50.0 ng/mL were found as 82.05%, 80.94%, and 83.33%,
respectively. The overall average recovery of SF and SFD5











0.30 0.32 0.01 3.54
75.00 77.30 1.28 1.66
Processed sample
stability (61.5 h)
0.30 0.30 0.01 2.08
75.00 78.83 0.67 0.84
Long term stability
(45 days)
0.30 0.32 0.02 6.08
75.00 71.93 2.90 4.03
Freeze-thaw stability
(cycle 3, 48 h)
0.30 0.32 0.01 3.51
75.00 77.65 0.59 0.76Pharmacokinetics and statistical analysis
The validated method has been successfully applied to
quantify SF concentrations into a single dose (4 mg/
200 g body weight of rat) in rats. The pharmacokinetic
parameters evaluated were Cmax (maximum observed
drug concentration during the study), AUC0 to 72 (area
under the plasma concentration-time curve measured
24 h, using the trapezoidal rule), Tmax (time to observe
maximum drug concentration), Kel (apparent first-order
terminal rate constant calculated from a semi-log plot of
the plasma concentration versus time curve, using the
method of least square regression), and T1/2 (terminal
half-life as determined by quotient 0.693/Kel). Pharma-
cokinetic details are shown in Table 4. The mean con-
centration versus time profile of SF in rat plasma is
shown in Figure 5 FDA (2002), FDA (2003) Guidence.
Conclusions
The method described in this manuscript has been
developed and validated over the concentration range
of 0.1 to 100.0 ng/mL in rat plasma. The intrabatch pre-
cision was less than 4.84% and accuracy ranged from
101.21% to 106.67%. The interbatch precision was lessFigure 5 Mean plasma concentration versus time graph of
Solifenacin after oral administration of 4 mg dose in 200 g rat.
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104.79%. The selectivity, sensitivity, precision, and accur-
acy obtained with this method make it suitable for
the purpose of the present study. The simplicity of the
method, and using rapid liquid-liquid extraction and
sample turnover rate of 2.0 min per sample, makes it an
attractive procedure in high-throughput bioanalysis of
Solifenacin. The validated method was successfully ap-
plied in the pharmacokinetic study of rats by oral ad-
ministration of 4 mg/200 g in six healthy rats.
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